4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
4.790
+0.440 (10.11%)
At close: Jun 9, 2025, 4:00 PM
4.750
-0.040 (-0.84%)
After-hours: Jun 9, 2025, 7:30 PM EDT
4D Molecular Therapeutics Stock Forecast
FDMT's stock price has decreased by -78.92% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for 4D Molecular Therapeutics stock ranges from a low of $6.00 to a high of $44. The average analyst price target of $32.33 forecasts a 574.95% increase in the stock price over the next year.
Price Target: $32.33 (+574.95%)
Analyst Consensus: Buy
* Price targets were last updated on May 9, 2025.
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $28 → $25 | Strong Buy | Maintains | $28 → $25 | +421.92% | May 9, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $51 → $44 | Strong Buy | Maintains | $51 → $44 | +818.58% | May 9, 2025 |
| Barclays | Barclays | Buy Maintains $45 → $38 | Buy | Maintains | $45 → $38 | +693.32% | May 9, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $42 → $40 | Strong Buy | Maintains | $42 → $40 | +735.07% | Mar 10, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +484.55% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
5.56M
from 37.00K
Increased by 14,927.03%
Revenue Next Year
4.85M
from 5.56M
Decreased by -12.86%
EPS This Year
-3.62
from -2.98
EPS Next Year
-3.99
from -3.62
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 21.0M | 21.0M | ||
| Avg | 5.6M | 4.8M | 4.0M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 56,656.8% | 277.7% | 333.4% | ||
| Avg | 14,927.0% | -12.9% | -17.3% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.31 | -2.94 | -1.63 | ||
| Avg | -3.62 | -3.99 | -4.02 | ||
| Low | -3.98 | -5.04 | -6.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.